ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,164Medicare Part D Prescriptions Filled, Including Refills

Rank: 160 out of 1692

$526K Total Retail Price of All Prescriptions

Rank: 224 out of 1692

695 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
28% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Virginia
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 695 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

7% of this provider’s 695 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 10,304 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Virginia
SIMVASTATIN 505 471 1 1
AMLODIPINE BESYLATE 435 396 2 3
LEVOTHYROXINE SODIUM 431 414 3 4
LISINOPRIL 342 325 4 2
OMEPRAZOLE 318 293 5 5
METOPROLOL TARTRATE 283 270 6 10
PRAVASTATIN SODIUM 272 255 7 12
HYDROCHLOROTHIAZIDE 248 229 8 9
LOSARTAN POTASSIUM 233 209 9 17
CITALOPRAM HBR 229 171 10 21
ATORVASTATIN CALCIUM 223 207 11 11
METFORMIN HCL 220 179 12 8
FUROSEMIDE 218 174 13 7
ATENOLOL 193 138 14 15
CRESTOR 193 192 14 26
TRAMADOL HCL 174 164 16 16
CARVEDILOL 165 157 17 24
WARFARIN SODIUM 163 161 18 14
GABAPENTIN 161 143 19 13
ZOLPIDEM TARTRATE 157 125 20 23
HYDROCODONE-ACETAMINOPHEN 142 130 S3 21 6
DONEPEZIL HCL 137 134 22 29
POTASSIUM CHLORIDE 124 120 23 20
MELOXICAM 113 103 24 41
TAMSULOSIN HCL 112 112 25 31
POLYETHYLENE GLYCOL 3350 107 107 26 64
GLIMEPIRIDE 106 95 27 32
NEXIUM 104 92 28 25
SERTRALINE HCL 100 97 29 22
ALENDRONATE SODIUM 99 94 30 36
FLUTICASONE PROPIONATE 98 92 31 27
METOPROLOL SUCCINATE 94 90 32 18
CLOPIDOGREL 86 84 33 43
LOVASTATIN 86 67 33 37
PANTOPRAZOLE SODIUM 85 84 35 39
LISINOPRIL-HYDROCHLOROTHIAZIDE 85 72 35 19
BENAZEPRIL HCL 72 72 37 69
AMITRIPTYLINE HCL 69 56 R 38 58
NAMENDA 68 67 39 50
QUETIAPINE FUMARATE 64 59 40 62
ZETIA 63 63 41 68
TRAZODONE HCL 62 62 42 33
CELEBREX 61 60 43 103
ADVAIR DISKUS 58 52 44 45
AZITHROMYCIN 57 49 45 34
AVODART 56 56 46 173
VENLAFAXINE HCL ER 52 47 47 84
PRADAXA 52 52 47 308
ESCITALOPRAM OXALATE 52 52 47 76
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.